Modern oncology has witnessed innovations with targeted therapies that affect specific biological processes that lead to cancer. This ranges from small molecules to monoclonal antibodies. The most notable and dramatic change in oncology therapy has been the use of agents that regulate the cell cycle, providing a better opportunity to treat and overcome cancer. In this context, Palbociclib  has shown enormous potential in managing hormone receptor-positive, HER2-negative advan